FDA Pediatric Exclusivity Standard Shifts: Is Request “Fairly Met”?
Executive Summary
The Mevacor pediatric exclusivity case is driving FDA to take a less literal approach to analyzing responses to written requests for studies
You may also be interested in...
Pediatric Bills' Generic Approval "Carve-Out" Needs Refinement, Hatch Says
Provisions of bills to renew the pediatric exclusivity program which allow for approval of generics despite protected labeling by innovators should be revised, Sen. Orrin Hatch (R-Utah) said.
Pediatric research in cancer
FDA's Oncologic Drugs/Pediatric Subcommittee will meet Nov. 28 to discuss implementation of the pediatric rule including study design, ethical issues and extrapolating findings from adult to pediatric patients. The meeting will be held at the Holiday Inn in Gaithersburg, Md. beginning at 8 a.m
Merck Mevacor Exclusivity Will Run Until Dec. 15 Following FDA Reversal
FDA is granting Merck pediatric exclusivity for Mevacor (lovastatin) through Dec. 15 following consideration of clarified data submitted by the company.